Literature DB >> 16412784

Pathophysiology of graft-versus-host disease.

James L M Ferrara1, Pavan Reddy.   

Abstract

Complications of allogeneic hematopoietic stem cell transplantation (HSCT) remain barriers to its wider application for a variety of diseases. Graft-versus-host disease (GVHD) is the major cause of morbidity and mortality following allogeneic HSCT. GVHD can be considered an exaggerated, undesirable manifestation of a normal inflammatory mechanism, in which donor lymphocytes encounter foreign antigens in a milieu that fosters inflammation. Recent advances in the study of cytokine networks, chemokine gradients, and the direct mediators of cellular cytotoxicity have led to improved understanding of this complex syndrome. The pathophysiology of acute GVHD can be considered as a three-step process in which the innate and adaptive immune systems interact: (1) tissue damage to the recipient by the radiation/chemotherapy pretransplant conditioning regimen; (2) donor T-cell activation and clonal expansion; and (3) cellular and inflammatory factors. Here we review the immunologic interactions that cause clinical GVHD and discuss the risk factors and prophylactic strategies for acute GVHD according to this model.

Entities:  

Mesh:

Year:  2006        PMID: 16412784     DOI: 10.1053/j.seminhematol.2005.09.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  110 in total

1.  Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.

Authors:  Johannes K-H Meier; Daniel Wolff; Steve Pavletic; Hildegard Greinix; Martin Gosau; Hartmut Bertz; Stefanie J Lee; Anita Lawitschka; Sharon Elad
Journal:  Clin Oral Investig       Date:  2010-09-22       Impact factor: 3.573

2.  The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.

Authors:  Minghui Li; Kai Sun; Doug Redelman; Lisbeth A Welniak; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

Review 3.  GVHD: a continuing barrier to the safety of allogeneic transplantation.

Authors:  Pavan Reddy; Mukta Arora; Martin Guimond; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

4.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

5.  Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

Authors:  Nancy Y Villa; Clive H Wasserfall; Amy M Meacham; Elizabeth Wise; Winnie Chan; John R Wingard; Grant McFadden; Christopher R Cogle
Journal:  Blood       Date:  2015-04-22       Impact factor: 22.113

6.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

7.  Ceramide synthesis regulates T cell activity and GVHD development.

Authors:  M Hanief Sofi; Jessica Heinrichs; Mohammed Dany; Hung Nguyen; Min Dai; David Bastian; Steven Schutt; Yongxia Wu; Anusara Daenthanasanmak; Salih Gencer; Aleksandra Zivkovic; Zdzislaw Szulc; Holger Stark; Chen Liu; Ying-Jun Chang; Besim Ogretmen; Xue-Zhong Yu
Journal:  JCI Insight       Date:  2017-05-18

8.  Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.

Authors:  D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

9.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

10.  The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD.

Authors:  Lequn Li; Hui Wang; Jin sub Kim; German Pihan; Vassiliki Boussiotis
Journal:  Cell Cycle       Date:  2009-06-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.